Lilly Moves Ahead With $10M Solar Panel Project For Two Indy Corporate Campuses
Eli Lilly and Co. is moving ahead with a $10 million solar panel installation project on their two Indianapolis corporate campuses.
Read MoreEli Lilly and Co. is moving ahead with a $10 million solar panel installation project on their two Indianapolis corporate campuses.
Read MoreOver a decade ago, Eli Lilly and Co. was struggling.
Read MoreGov. Eric Holcomb on Wednesday defended his signing of a near-total abortion ban this month and brushed off fears of business and talent attraction consequences in the wake of ominous statements from major homegrown employers.
Read MoreBy DAN MCGOWAN Writer/Reporter, Inside Indiana Business A potential rheumatoid arthritis treatment being co-developed by Indianapolis-based Eli Lilly and Co. and Incyte Corp. continues to return positive results in late-stage testing. In a recent phase-three global study, Lilly says baricitinib met its primary endpoint. The results have been published in … Read More
By ANDY OBER Assistant Managing Editor InsideIndianaBusiness INDIANAPOLIS — The U.S. Food and Drug Administration has approved a type 2 diabetes treatment from Indianapolis-based Eli Lilly and Co. and Boehringer Ingelheim Pharmaceuticals Inc. Synjardy was also approved earlier this year by the European Medicines Agency. Lilly says Synjardy is the … Read More
Eli Lilly and Company (NYSE: LLY) yesterday announced that it has completed the acquisition of Novartis Animal Health, which will further position Lilly’s Elanco as a global leader in the animal health industry. The transaction, first announced on April 22, has received clearance under the Hart-Scott-Rodino Antitrust Improvements … Read More
Eli Lilly and Company (NYSE: LLY) has received its third US Food and Drug Administration (FDA) approval for CYRAMZA® (ramucirumab). Specifically, CYRAMZA is now also indicated in combination with docetaxel, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy. Patients … Read More
Eli Lilly and Company (NYSE: LLY) and AstraZeneca yesterday announced enrollment of the first patient into AMARANTH, a Phase II/III study of an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer’s disease. AZD3293, also known as LY3314814, has been shown … Read More